GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Caliway Biopharmaceuticals Co Ltd (TPE:6919) » Definitions » Revenue

Caliway Biopharmaceuticals Co (TPE:6919) Revenue : NT$44.43 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Caliway Biopharmaceuticals Co Revenue?

Caliway Biopharmaceuticals Co's revenue for the three months ended in Dec. 2024 was NT$9.36 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2024 was NT$44.43 Mil. Caliway Biopharmaceuticals Co's Revenue per Share for the three months ended in Dec. 2024 was NT$0.06. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was NT$0.31.

Warning Sign:

Caliway Biopharmaceuticals Co Ltd revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Caliway Biopharmaceuticals Co was -1.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was 5.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was -5.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 6 years, Caliway Biopharmaceuticals Co's highest 3-Year average Revenue per Share Growth Rate was 17.40% per year. The lowest was -41.00% per year. And the median was 5.10% per year.


Caliway Biopharmaceuticals Co Revenue Historical Data

The historical data trend for Caliway Biopharmaceuticals Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Caliway Biopharmaceuticals Co Revenue Chart

Caliway Biopharmaceuticals Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Revenue
Get a 7-Day Free Trial 10.35 12.34 12.82 38.93 44.43

Caliway Biopharmaceuticals Co Quarterly Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.91 3.97 7.85 23.26 9.36

Competitive Comparison of Caliway Biopharmaceuticals Co's Revenue

For the Biotechnology subindustry, Caliway Biopharmaceuticals Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Caliway Biopharmaceuticals Co's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Caliway Biopharmaceuticals Co's Revenue distribution charts can be found below:

* The bar in red indicates where Caliway Biopharmaceuticals Co's Revenue falls into.


;
;

Caliway Biopharmaceuticals Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$44.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Caliway Biopharmaceuticals Co  (TPE:6919) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Caliway Biopharmaceuticals Co Revenue Related Terms

Thank you for viewing the detailed overview of Caliway Biopharmaceuticals Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Caliway Biopharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
No.99, Sec. 1, Xintai 5th Road, 32rd Floor-9, Xizhi District, New Taipei City, TWN, 221
Caliway Biopharmaceuticals Co Ltd is specialized in the development of new drugs for medical aesthetic and inflammatory diseases. Its pipeline candidate is, CBL-514, CBA-539, and CBO-012.

Caliway Biopharmaceuticals Co Headlines

No Headlines